期刊文献+

N-甲基异噻唑酮取代的间苯二甲酸衍生物的设计、合成及其抑制β-分泌酶活性 被引量:2

Design,synthesis and inhibitory activity against β-secretase of N-methyl isothiazolone substituted isophthalic acid derivatives
原文传递
导出
摘要 目的发现新结构的β-分泌酶抑制剂。方法基于β-分泌酶抑制剂的构效关系,设计合成了含羟乙胺结构片段的间位1,1-二氧代-N-甲基-2,3-(2H)-异噻唑酮取代的间苯二甲酸衍生物;采用时间分辨荧光法检测化合物对β-分泌酶的抑制活性。结果合成了8个目标化合物,利用MS和1H-NMR对化合物的结构进行了确证,利用HPLC对化合物的纯度进行了测定,利用旋光仪测定了化合物的比旋光度;活性数据显示有2个化合物对β-分泌酶有较强的抑制作用,其中化合物2c的IC50值为3.7 nmol.L-1。结论发现了新的β-分泌酶抑制剂,分析了其初步的构效关系,为进一步进行结构优化进而发现活性更好的化合物奠定了基础。 The introduction of β-amyloid hypothesis offers an alternative strategy of discovering new drug for the treatment of AD. According to the hypothesis, abnormal accumulation and deposition of β-amyloid peptides(Aft) in brain,which have neurological toxicity ,cause pallium to result in Alzheimer's disease, β-Amy- loid peptide is produced from amyloid precursor protein(β-APP) by gradually hydrolization with β-secretase (BACE-1) and γ-secretase. BACE-1 is a rate limiting enzyme of the generation ofβ-amyloid peptides, so it might be an ideal target of interfering in the process of Alzheimer's disease. Based on the structural feature of active site of β-secretase binding to the typical inhibitors and the structure of β-secretase inhibitors disco- vered in our laboratory, N-methyl isothiazolone substituted isophthalic acid derivatives were designed and synthesized. Eight target compounds were synthesized and their structures were confirmed by 1H-NMR and MS. The purity of these compounds was determined by HPLC. Time-resolved βuorescence method was used to evaluate inhibitory activity of these compounds against BACE-1. The results showed that four of these compounds had obvious inhibitory activity against β-secretase. Especially, the IC50 value of compound 2c and 2d against β-secretase was 3.7 and 12. 3 nmol. L-j respectively. Based on biological evaluation of target compounds against BACE-1 in vitro as well as Surβex Model of Sybyl 8.1 program to simulate interaction of target cpmpounds with BACE-1, the initial structure-activity relationship of these β-secretase inhibitors were summarized: 1 ) Inhibitory activity can be improved when P2' fragment is aromatic group because this group can generate π-π stacking interaction with Y198 residue of BACE-1 S2' subsite. 2) It is more advan-tageous to improve activity when P3' fragment is α-methylbenzylamine group. 3 ) When P2 fragment of 8- secretase inhibitor is 1,1-dioxido-N-methyl-2,3-(2H)-isothiazolone, aromatic groups used as P3, PI and P2' fragments are prefered to improve inhibitory activity against β-secretase. These results are useful to design and optimize the structure of this series of compounds and provide a direction to find more excellent BACE-I inhibitors with potent activity and selectivity in the future.
出处 《中国药物化学杂志》 CAS CSCD 2011年第6期415-422,共8页 Chinese Journal of Medicinal Chemistry
基金 国家自然科学基金课题(81172924) 北京市自然科学基金课题(7112106)
关键词 Β-分泌酶 抑制剂 设计 合成 构效关系 β-secretase inhibitor design synthesis structure-activity relationship
  • 相关文献

参考文献12

  • 1HARDY J A, HIGGINS G A. Alzheimer's disease: the amyloid cascade hypothesis [ J ]. Science, 1992, 256(5054) : 184 - 185.
  • 2SHANTA B, YONA L, MICHAEL R S. Inhibiting β- secretase activity in Alzheimer's disease cell models with single chain antibodies specifically targeting APP[ J]. J Mol Biol,2011,405(2) :436 -447.
  • 3COLE S L, VASSAR R. BACE1 structure and func- tion in health and Alzheimer' s disease [ J ]. Curr Alzheimer Res ,2008,5 (2) : 100 - 120.
  • 4ROBERDS S L, ANDERSON J, BASI G, et al. BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain:implications for Alzheimer's disease therapeutics[ J]. Hum Mol Gen- et,2001,10(12) : 1317 - 1324.
  • 5LUO Y, BOLON B, KAHN S, et al. Mice deficient in BACE1 ,the Alzheimer's β-secretase,have normal phenotype an dabolished β-amyloid generation [J ]. Nat Neurosci,2001,4 (3) :231 - 232.
  • 6高善云,顾为,程军平,程肖蕊,周文霞,聂爱华.异噻唑酮取代的间苯二甲酸衍生物的设计、合成及其抑制β-分泌酶活性[J].中国药物化学杂志,2010,20(6):467-475. 被引量:2
  • 7BEAULIEU P L, WERNIC D. Preparation of amino- alkyl chlorohydrin hydrochlorides: key building blocks for hydroxyethylamines-based HIV protease inhibitors[ J]. J Org Chem, 1996,61 ( 11 ) :3635 - 3645.
  • 8NG J S, PRZYBYLA C A, LIU C, et al. A practical synthesis of an HIV protease inhibitor intermediate- diastereoselective epoxide formation from chiral α- aminoaldehydes [ J ]. Tetrahedron, 1995, 51 ( 23 ) : 6397 - 6410.
  • 9LEWIS S N, MILLER G A, HAUSMAN M. Isothia- zoles I: 4-isothiazolin-3-ones. A general synthesis from 3,3'-dithiodipropionamides [ J ]. J Heterocycl Chem,1971,8(4) :571 -580.
  • 10MARIA A A, MARCIAL M M, FERNANDO L, et al. Electrospray ionization mass spectrometry detec- tion of intermediates in the palladium-catalyzed oxi- dative self-coupling of areneboronic acids [ J ]. J Org Chem, 1999,64 (10) :3592 - 3594.

二级参考文献15

  • 1HARDY J,HIGGINS G A. Alzheimer's diseases:the amyloid cascade hypothesis [ J]. Science, 1992,256 (5054) : 184 - 185.
  • 2SELKOE D J. Translating cell biology into therapeu- tic advances in Alzheimer' s diseases [ J ]. Nature, 1999,399(6738 Suppl) :A23 - A3t.
  • 3GHOSH A K,KUMARAGURUBARAN N, HONG L,et al. Design, synthesis, and X-ray structure of po- tent memapsin 2(β-secretase) inhibitors with isoph- thalamide derivatives as the P2-P3-ligands[ J]. J Med Chem,2007,50 (10) : 2399 - 2407.
  • 4YOSHIO H,YOSHIAKI K. Recent progress in the drug discovery of non-pepfidic BACE1 inhibitors[ J]. Expert Opin Drug Discov,2009,4(4) :391 -416.
  • 5GHOSH A K,SHIN D,DOWNS D,et al. Design of potent inhibitors for human brain memapsin 2 (beta- secretase) [ J ]. J Am Chem Soc, 2000, 122 ( 14 ) : 3522 - 3523.
  • 6HONG L,TURNER R T,KOELSCH G,et al. Crys- tal structure of memapsin 2(β-secretase) in complex with an inhibitor OM00-3 [ J ]. Biochemistry, 2002, 41 (36) : 10963 - 10967.
  • 7SHAWN J S, CRAIG A C, THOMAS G S, et al. Structure-based design of potent and selective cell- permeable inhibitors of human β-secretase( BACE-1 ) [J]. J Med them,2004,47(26) :6447 -6450.
  • 8CRAIG A C, SHAWN J S, KRISTEN G J, et al. BACE-1 inhibition by a series of ψ[CH2NH] re- duced amide isosteres [ J]. Bioorg Med Chem Lett, 2006,16(14) :3635 - 3638.
  • 9CHARRIER N, CLARKE B,CUTLER L,et al. Se- cond generation of hydroxyethylamine BACE-1 inhi- bitors: optimizing potency and oral bioavailability [ J]. J Med Chem ,2008 ,51 ( 11 ) :3313 -3317.
  • 10KORTUM S W,BENSON T E,BIENKOWSKI M J, et al. Potent and selective isophthalamide S2 hydroxy- ethylamine inhibitors of BACE1 [ J ]. Bioorg Med Chem Lett,2007,17 (12) :3378 - 3383.

共引文献1

同被引文献82

  • 1HARDY J A, HIGGINS G A. Alzheimer's disease: the amyloid cascade hypothesis[J]. Science, 1992, 256 (5054) : 184 - 185.
  • 2SHANTA B, YONA L, MICHAEL R S. Inhibiting β- secretase activity in Alzheimer's disease cell models with single chain antibodies specifically targeting APP [J]. J Mol Biol,2011,405(2) :436 -447.
  • 3COLE S L, VASSAR R. BACE1 structure and function in health and Alzheimer' s disease[J]. Curr Alzheimer Res ,2008,5 ( 2 ) : 100 - 120.
  • 4GHOSH A K, BRINDISI M, TANG J. Developing β- secretase inhibitors for treatment of Alzheimer's disease [J]. J Neurochem, 2012, 120 ( Suppl. 1 ) : 71 - 83.
  • 5HUSSAIN I, HAWKINS J, HARRISON D, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases t-cleavage of amyloid precursor protein and amyloid-β production in vivo [J]. J Neurochem,2007,100( 3 ) :802 - 809.
  • 6HAMADA Y, KISO Y. Recent progress in the drug discovery of non-peptidic BACE1 inhibitors [ J ]. Expert Opin Drug Discov,2009,4(4) :391 -416.
  • 7Hardy JA, Higgins GA. Alzheimer′s disease: the amyloid cascade hypothesis [J].Science, 1992, 256(5054): 184-185.
  • 8Deane R, Singh I, Sagare AP, et al. A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease [J].J Clin Invest, 2012, 122(4): 1377- 1392.
  • 9Vassar R, Kandalepas PC. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer′s disease [J].Alzheimers Res Ther, 2011, 3(3): 1-6.
  • 10Yuan J, Venkatraman S, Zheng Y, et al. Structure-based design of β-site APP cleaving enzyme 1 (BACE1) inhibitors for the treatment of alzheimer′s disease [J].J Med Chem, 2013, 56(11): 4156-4180.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部